[Special Stock] Samsung Pharmaceutical Rises Over 17% on 37 Billion KRW Drug Supply Contract
[Asia Economy Reporter Myung-Hwan Lee] Samsung Pharmaceutical is soaring amid a declining market on the morning of the 14th. This is interpreted as being influenced by the news of signing a pharmaceutical supply contract worth 37 billion KRW the previous day.
As of 9:58 AM today, Samsung Pharmaceutical is trading at 4,280 KRW, up 17.74% (645 KRW) from the previous trading day.
Samsung Pharmaceutical announced yesterday that it signed a pharmaceutical supply contract worth 36.9886 billion KRW with Ilhwa. The contract period is from the 13th of this month to December 31, 2026. The contract amount corresponds to 67.37% of last year's sales.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Under this contract, Samsung Pharmaceutical will exclusively supply 18 prescription drug items, including 'Doranjinju 50mg', to Ilhwa, and Ilhwa will exclusively sell them through domestic distribution channels. Ilhwa must guarantee the purchase of more than 90% of the expected annual sales. The contract includes a clause that allows Samsung Pharmaceutical to claim damages from Ilhwa if Ilhwa fails to meet the purchase guarantee condition.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
